<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0026-1742</journal-id>
<journal-title><![CDATA[Revista de la Facultad de Medicina (México)]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Fac. Med. (Méx.)]]></abbrev-journal-title>
<issn>0026-1742</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional Autónoma de México, Facultad de Medicina]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0026-17422017000500007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento farmacológico de la depresión: actualidades y futuras direcciones]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacological treatment of depression: current and future directions]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Esparza]]></surname>
<given-names><![CDATA[Rodrigo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Laboratorio de Investigación en Adicciones ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Departamento de Neuropsiguiatría ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2017</year>
</pub-date>
<volume>60</volume>
<numero>5</numero>
<fpage>7</fpage>
<lpage>16</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0026-17422017000500007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0026-17422017000500007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0026-17422017000500007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El trastorno depresivo mayor representa una de las principales causas de discapacidad a nivel mundial. Su neurobiología es compleja, e involucra factores genéticos, moleculares, neurofisiológicos y psicosociales. Las opciones de tratamiento incluyen la psicoterapia, los psicofármacos, la terapia electro-convulsiva, y la terapia magnética transcraneal y profunda. El tratamiento farmacológico disponible en la actualidad únicamente alcanza tasas de respuesta y remisión sintomática modestas. Los antidepresivos actuales, a pesar de sus distintos mecanismos de acción, tienen como común denominador la regulación de sistemas de neurotransmisión monoaminérgica (serotonina, noradrenalina, dopamina), y comparten similar eficacia. La elección del antidepresivo a utilizar debe individualizarse y basarse en las características sintomáticas del cuadro depresivo, comorbilidades, efectos secundarios, interacciones farmacológicas y disponibilidad. Por esta razón, el médico debe conocer los perfiles farmacológicos de los antidepresivos a profundidad. Los recientes avances en la investigadón sobre la neurobiología de la depresión involucran al sistema glutamatérgico como un contribuyente. A su vez, el descubrimiento de los efectos antidepresivos de la ketamin&#261;, un antagonista del receptor NMDA de gluta mato, ha abierto las puertas para el desarrollo de estrategias dirigidas a nuevos blancos terapéuticos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Major depressive disorder represents one of the main causes of disability worldwide. Its neurobiology is complex, involving genetic, molecular, neurophysiological and psychosocial fac&#1418;tors. Treatment options include psychotherapy, psychotropic medication, electroconvulsive therapy, and transcranial and deep magnetic stimulation. Currently available medication will only achieve modest response and remission rates. Current antidepressants have the common characteristic of regulating the monoaminergic neurotransmission systems (serotonin, noradrenaline, dopamine), regardless of their different mechanisms of action, and share similar efficacy. The choice of the antidepressant must be individualized and based on the symptomatic characteristics of the depressive episode, comorbidities, side effects, pharmacological interactions, and availability. For this reason, practitioners must be deeply familiar with the pharmacological profiles of the antidepressants. Recent advances in research on the neurobiology of depression have involved the glutamatergic system as a contributor. Also, the discovery of the antidepressant effects of ketamine, a glutamatergic NMDA receptor antagonist, has opened the doors to the development of strategies directed to new therapeutic targets]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Depresión]]></kwd>
<kwd lng="es"><![CDATA[antidepresivos]]></kwd>
<kwd lng="es"><![CDATA[ketamina]]></kwd>
<kwd lng="en"><![CDATA[Depression]]></kwd>
<kwd lng="en"><![CDATA[antidepressants]]></kwd>
<kwd lng="en"><![CDATA[ketamine]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>American Psychiatric Association</collab>
<source><![CDATA[Diagnostic and Statistical Manual of Mental Disorders]]></source>
<year>2013</year>
<edition>5</edition>
<publisher-loc><![CDATA[Washington, DC ]]></publisher-loc>
<publisher-name><![CDATA[American Psychiatric Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>Global Burden of Disease Study C</collab>
<article-title xml:lang=""><![CDATA[Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>386</volume>
<numero>9995</numero>
<issue>9995</issue>
<page-range>743-800</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luppino]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[de Wit]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Bouvy]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overweight, obesity, and depression a systematic review and meta-analysis of longitudinal studies]]></article-title>
<source><![CDATA[Arch Gen Psychiatry]]></source>
<year>2010</year>
<volume>67</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>220-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhar]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Barton]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Depression and the Link with Cardiovascular Disease]]></article-title>
<source><![CDATA[Front Psychiatry]]></source>
<year>2016</year>
<volume>7</volume>
<page-range>33</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina-Mora]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Benjet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Berglund]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychiatrie disorders in Mexico lifetime prevalence in a nationally representative sample]]></article-title>
<source><![CDATA[Br J Psychiatry]]></source>
<year>2007</year>
<volume>190</volume>
<page-range>521-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomez-Dantes]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fullman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lamadrid-Figueroa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dissonant health transition in the states of Mexico, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10058</numero>
<issue>10058</issue>
<page-range>2386-402</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borges G]]></surname>
<given-names><![CDATA[OR]]></given-names>
</name>
<name>
<surname><![CDATA[Benjet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Medina-Mora]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Suicidio conductas suicidas en México: retrospectiva y situación actual]]></article-title>
<source><![CDATA[Salud Pública de México]]></source>
<year>2010</year>
<volume>52</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>292-304</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>American Psychiatric Association</collab>
<source><![CDATA[Practice Guideline for the Treatment of Patients With Major Depressive Disorder]]></source>
<year>2010</year>
<edition>3</edition>
<publisher-loc><![CDATA[Arlington, VA ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Mcintosh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder Section 1. Disease Burden and Principles of Care]]></article-title>
<source><![CDATA[Can J Psychiatry]]></source>
<year>2016</year>
<volume>61</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>510-23</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaynes]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Warden]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Trivedi]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Wisniewski]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Fava]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rush]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What did STAR*D teach us Results from a large-scale, practical, clinical trial for patients with depresSion]]></article-title>
<source><![CDATA[Psychiatr Serv]]></source>
<year>2009</year>
<volume>60</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1439-45</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rush]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Trivedi]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Wisniewski]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps a STAR*D report]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>2006</year>
<volume>163</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1905-17</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hillhouse]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Porter]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A brief history of the development of antidepressant drugs from monoamines to glutamate]]></article-title>
<source><![CDATA[Exp Clin Psychopharmacol]]></source>
<year>2015</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-21</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirschfeld]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[History and evolution of the monoamine hypothesis of depression]]></article-title>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>2000</year>
<volume>61</volume>
<numero>^s6</numero>
<issue>^s6</issue>
<supplement>6</supplement>
<page-range>4-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hao]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New hypothesis and treatment targets of depression an integrated view of key findings]]></article-title>
<source><![CDATA[Neuroser Bull]]></source>
<year>2015</year>
<volume>31</volume>
<numero>l</numero>
<issue>l</issue>
<page-range>61-74</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kupfer]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Frank]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Major depressive disorder new clinical, neurobiological, and treatment perspectives]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>379</volume>
<numero>9820</numero>
<issue>9820</issue>
<page-range>1045-55</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Daly]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[O'Donovan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic architectures of psychiatric disorders the emerging picture and its implications]]></article-title>
<source><![CDATA[Nat Rev Genet]]></source>
<year>2012</year>
<volume>13</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>537-51</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dowlati]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Herrmann]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Swardfager]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A meta-analysis of cytokines in major depression]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>2010</year>
<volume>67</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>446-57</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lener]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Niciu]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ballard]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Mcintyre]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical Guidelines for the Management of Adults with Major Depressive Disorder Section 3. Pharmacological Treatments]]></article-title>
<source><![CDATA[Can J Psychiatry]]></source>
<year>2016</year>
<volume>61</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>540-60</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stahl]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[Stahls Essential Psychopharmacology: Neuroserentific Basis and Practical Applications. New York,]]></source>
<year>2013</year>
<publisher-loc><![CDATA[United States of America ]]></publisher-loc>
<publisher-name><![CDATA[Cambridge University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gartlehner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder an updated meta-analysis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2011</year>
<volume>155</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>772-85</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khoo]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Teng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2015</year>
<volume>29</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>695-712</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramsberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Asseburg]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Henriksson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness and cost-effectiveness of antidepressants in primary care a multiple treatment comparison meta-analysis and cost-effectiveness model]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2012</year>
<volume>7</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Linde]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kriston]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rucker]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care systematic review and network meta-analysis]]></article-title>
<source><![CDATA[Ann Fam Med]]></source>
<year>2015</year>
<volume>13</volume>
<numero>l</numero>
<issue>l</issue>
<page-range>69-79</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berman]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Cappiello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antidepressant effects of ketamine in depressed patients]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>2000</year>
<volume>47</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>351-4</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheuing]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Chuang DM]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antidepressant mechanism of ketamine perspective from preclinical studies]]></article-title>
<source><![CDATA[Front Neuroser]]></source>
<year>2015</year>
<volume>9</volume>
<page-range>249</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kishimoto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chawla]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hagi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression a meta-analysis of efficacy, safety and time trajectories]]></article-title>
<source><![CDATA[Psychol Med]]></source>
<year>2016</year>
<volume>46</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>l459-72</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romeo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Choucha]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Fossati]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rotge]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression]]></article-title>
<source><![CDATA[Psychiatry Res]]></source>
<year>2015</year>
<volume>230</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>682-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGirr]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Berlim]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Bond]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy efficacy and tolerability]]></article-title>
<source><![CDATA[J Psychiatr Res]]></source>
<year>2015</year>
<volume>62</volume>
<page-range>23-30</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murrough]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Soleimani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[DeWilde]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ketamine for rapid reduction of suicidal ideation a randomized controlled trial]]></article-title>
<source><![CDATA[Psychol Med]]></source>
<year>2015</year>
<volume>45</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>3571-80</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
